Metastases to central nervous system+1
Not recruitingStudy of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases
Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases
- Disease:Metastases to central nervous systemHER2 negative breast cancer
- Substances:Trastuzumab Deruxtecan
Spain- Participants:18–64 years · 65+ years
- Substances:Trastuzumab Deruxtecan
- Sponsor:Medica Scientia Innovation Research S.L.










